Condition: B-cell Lymphoma · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma
This description comes directly from the study's public registry record.
Zengjun Li, Doctor · 13642138692 · zengjunli@163.com
Fei Li, Doctor · 13970038386 · yx021021@sina.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinise Academy of Medical Sciences | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Gansu Provincial Cancer Hospital | Lanzhou, Gansu, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Guigang City People's Hospital | Guigang, Guangxi, China | Not Yet Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Not Yet Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| PuYang AnYang District Hospital | Anyang, Henan, China | Not Yet Recruiting |
| Puyang People's Hospital | Puyang, Henan, China | Not Yet Recruiting |
| Henan Provincial People's Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University | Zhengzhou, Henan, China | Not Yet Recruiting |
| Union Hosiptal, Tongji Medical College, Huazhong University of Science And Technolocy | Wuhan, Hubei, China | Not Yet Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06566586